Cisplatin versus carboplatin in NSCLC: is there one "best" answer? (Q37395888)

20 August 2017

1 reference

title

Cisplatin versus carboplatin in NSCLC: is there one "best" answer? (English)

1 reference

20 August 2017

1 reference

1 reference

Rachel E Sanborn

1

1 reference

20 August 2017

1 December 2008

1 reference

Current Treatment Options in Oncology

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

4-6

1 reference

20 August 2017

326-342

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-009-0085-5

20 August 2017

0 references

cites work

Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-009-0085-5

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-009-0085-5

Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe

21 January 2018

1 reference

12 December 2020

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

12 December 2020

Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.

1 reference

12 December 2020

Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer

1 reference

12 December 2020

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology

1 reference

12 December 2020

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

12 December 2020

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

1 reference

12 December 2020

Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group,

1 reference

12 December 2020

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

1 reference

12 December 2020

Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial

1 reference

12 December 2020

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

1 reference

12 December 2020

Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy

1 reference

12 December 2020

Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

1 reference

12 December 2020

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

1 reference

12 December 2020

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

1 reference

12 December 2020

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

1 reference

12 December 2020

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer

1 reference

12 December 2020

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

12 December 2020

Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

12 December 2020

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

1 reference

12 December 2020

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer

1 reference

12 December 2020

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.

1 reference

12 December 2020

Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504).

1 reference

12 December 2020

A Phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly.

1 reference

12 December 2020

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

12 December 2020

Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).

1 reference

12 December 2020

Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.

1 reference

12 December 2020

Prevalence of poor performance status in lung cancer patients: implications for research

1 reference

12 December 2020

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

12 December 2020

Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer

1 reference

12 December 2020

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

1 reference

12 December 2020

Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

10.1007/S11864-009-0085-5

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19225891